Clinical Trials on Human Immunodeficiency Virus Infection (HIV) in United States

Total 10768 results

National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

Human Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus Prevention

United States
GlaxoSmithKline

Completed

A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.

HIV Infection | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.

HIV Infection | Infection, Human Immunodeficiency Virus

United States
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Being Responsible for Ourselves HIV Risk Reduction for Black MSM (BRO)

Sexually Transmitted Disease (STD) | Human Immunodeficiency Virus Infection (HIV)

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

Infection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and Herpesviridae

United States
Merck Sharp & Dohme LLC

Recruiting

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection

United States, Mexico, Russian Federation, South Africa, Thailand
RTI International
Centers for Disease Control and Prevention

Completed

Positive Health Check Evaluation Trial ((PHC))

Human Immunodeficiency Virus (HIV) Positive

United States
MacroGenics
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Active, not recruiting

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Human Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1

United States
M.D. Anderson Cancer Center

Completed

Attitudes and Beliefs and the Steps of HIV Care

Human Immunodeficiency Virus Infections

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Human Immunodeficiency Virus (HIV)-1 Infection

United States, Spain, Germany, Dominican Republic
National Cancer Institute (NCI)

Completed

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

Acquired Immunodeficiency Syndrome | HIV Infection

United States
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (PROTEA)

Human Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) Virus

France, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
ViiV Healthcare

Completed

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Italy
Auritec Pharmaceuticals
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women

Human Immunodeficiency Virus (HIV) Prophylaxis

United States
GlaxoSmithKline

Completed

A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus

United States, Puerto Rico
VA Eastern Colorado Health Care System
Public Health Grant Program, Veterans Health Administration Office of Public...

Completed

Veterans Living With HIV/AIDS: A Pilot Study Examining Risk Factors Associated With Self-Directed Violence

Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) | Self-Directed Violence

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (ING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

HIV Infection | Infection, Human Immunodeficiency Virus I

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Terminated

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

HIV Infections | Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults

Infection, Human Immunodeficiency Virus | HIV-1 Infection

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Drug-drug Interaction (DDI) Rifabutin

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

GSK706769 Repeat Dose Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

HIV Infections | Infection, Human Immunodeficiency Virus

United States
Bristol-Myers Squibb

Completed

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat (Atazanavir)

Human Immunodeficiency Virus Type 1 (HIV-1)

United States
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Reality Check: An HIV Risk Reduction Serial Drama (RC)

Sexually Transmitted Diseases | HIV (Human Immunodeficiency Virus)

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
Glaxosmithkline/Quintiles

Completed

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between Dolutegravir and Prednisone

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

DDI Study of Etravirine and GSK1265744

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Bristol-Myers Squibb
Medarex

Completed

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV)

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
GlaxoSmithKline

Completed

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

HIV Infection | Infection, Human Immunodeficiency Virus

United States, Belgium, France, Germany, Spain, Canada, Italy, Portugal, Romania, Austria, Switzerland, Poland, Latvia, Luxembourg
Fred Hutchinson Cancer Center
University of Washington

Completed

MMF for HIV Reservoir Reduction

Human Immunodeficiency Virus I Infection

United States
ViiV Healthcare
GlaxoSmithKline

Terminated

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Infection, Human Immunodeficiency Virus

United States

Clinical Trials on Human Immunodeficiency Virus Infection (HIV) in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations